Wegovy Dosing: What the Schedule Really Means for Your Treatment

The myth that a higher dose always means better results, faster

This is a question our prescribers hear most weeks: "Can I skip ahead to 2.4 mg sooner?" The assumption behind it is understandable, if 2.4 mg is the therapeutic target, why spend four months working up to it? The honest answer is that the titration schedule isn't cautious box-ticking. Semaglutide slows gastric emptying and acts on appetite centres in the brain; introduce too much too quickly and nausea, vomiting and diarrhoea can become severe enough to force people off treatment altogether. The ramp-up exists to let your body adapt so you can actually stay on the dose that works.

Trial evidence backs this up. In the STEP 1 trial, published in the New England Journal of Medicine, participants who completed the full 68-week study at 2.4 mg lost around 15% of body weight on average. That outcome depends on reaching and sustaining maintenance, neither of which happens reliably when someone pushes the titration and drops out early because of side effects. Slower is often faster in practice.

There is also a clinical ceiling myth worth correcting: 2.4 mg was the standard maintenance dose when Wegovy launched. Since April 2026 a 7.2 mg maintenance option has been licensed by the MHRA for adults with a BMI of 30 or above, following trial data showing around 20.7% average weight reduction at 72 weeks. Whether that higher dose is appropriate for you is a clinical decision, not a self-selection one.

How the Wegovy dose steps actually work in practice

The licensed UK schedule runs: 0.25 mg for four weeks, 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, then 2.4 mg as the ongoing maintenance dose. You can find the step-by-step breakdown in the Wegovy dosing chart, which maps out the timing clearly. Each pen in the Wegovy range is pre-filled and pre-set to its dose, there is no dial to adjust. You inject once a week, on the same day each week, into the abdomen, thigh or upper arm, rotating the site.

A few practical points that matter more than people realise. The day of the week is flexible: you can shift it by a day or two to suit your routine, but your prescriber should know. If a dose is missed, the guidance in the Patient Information Leaflet sets out what to do based on how much time has passed, follow that rather than doubling up. Storage is straightforward: refrigerate between 2°C and 8°C; the leaflet gives the room-temperature window for when you're away from a fridge, and that window is shorter than most people expect.

The connection between dosing and weight loss outcomes is worth reading alongside the schedule, because the clinical evidence for each dose level tells a nuanced story about what to expect at each stage of treatment.

Eligibility for Wegovy and what the prescriber is assessing

The licensed eligibility criteria for Wegovy in the UK are a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. That's the starting point, not the whole picture. A prescriber also considers your medical history, current medicines and any contraindications before agreeing to prescribe. Wegovy is not licensed for people under 18, is not recommended during pregnancy or breastfeeding, and carries specific precautions for conditions including a personal or family history of thyroid tumours or pancreatitis.

NICE's guidance on semaglutide for weight management (TA875) sets out additional criteria for NHS access, including use within a specialist weight management service and a two-year maximum duration. The full Wegovy overview covers both the NHS and private routes so you can see where you sit. For cost context across providers, the price landscape for Wegovy in the UK is worth reading before you commit anywhere.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, your prescriber will factor that in during assessment. BMI is one input, not the final word.

When to get medical help during Wegovy treatment

Most people notice gastrointestinal side effects (nausea, loose stools, constipation, reflux) most strongly in the first weeks after starting or after a dose increase. These typically ease within one to two weeks. Drinking enough water matters more than people realise; prolonged vomiting or diarrhoea can cause dehydration quickly.

Some symptoms need prompt medical attention rather than waiting. Severe, persistent stomach pain that radiates towards the back, with or without vomiting, can indicate pancreatitis, the MHRA has specifically highlighted this risk in its Drug Safety Updates for GLP-1 medicines. Allergic reactions, gallbladder pain, rapid heartbeat or any sudden change in mood or thoughts about self-harm also require urgent assessment. Report any suspected side effects, including concerns about your medicine's authenticity, at the MHRA's Yellow Card scheme. That's not a formality, it directly informs ongoing safety monitoring for medicines like Wegovy.

If you're considering a micro-dosing approach to manage tolerability, discuss it with your prescriber first. Adjusting outside the licensed schedule without clinical oversight carries real risks that the titration design was built to avoid.